Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 randomized, double-blind, placebo-controlled, multi-center clinical study on the safety and effectiveness of Cyclosporine Eye Drops 0.09% for the treatment of keratoconjunctivitis sicca

Next Previous
Trial Profile

Phase 3 randomized, double-blind, placebo-controlled, multi-center clinical study on the safety and effectiveness of Cyclosporine Eye Drops 0.09% for the treatment of keratoconjunctivitis sicca

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Keratoconjunctivitis sicca
  • Focus Adverse reactions; Registrational; Therapeutic Use

Most Recent Events

  • 06 Jul 2020 New trial record
  • 30 Jun 2020 According to a China Medical System media release, Cyclosporine Eye Drops 0.09% has been granted a clinical trial notice issued by the National Medical Products Administration of the Peoples Republic of China on 30 June 2020 and agreed to carry out this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top